Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease

被引:11
作者
Lenka, Abhishek [1 ]
Di Maria, Gianluca [1 ]
Lamotte, Guillaume [2 ]
Bahroo, Laxman [1 ]
Jankovic, Joseph [3 ,4 ]
机构
[1] Medstar Georgetown Univ Hosp, Dept Neurol, Washington, DC USA
[2] Univ Utah, Dept Neurol, Salt Lake City, UT USA
[3] Baylor Coll Med, Parkinsons Dis Ctr, Houston, TX 77030 USA
[4] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, Houston, TX 77030 USA
关键词
Benserazide; carbidopa; levodopa; orthostasis; parkinson's disease; CARBIDOPA INTESTINAL GEL; L-DOPA; ORTHOSTATIC HYPOTENSION; DOUBLE-BLIND; MOTOR SYMPTOMS; THERAPY; PHARMACOKINETICS; PLACEBO; LEVODOPA/CARBIDOPA; GASTROPARESIS;
D O I
10.1080/14737175.2022.2091436
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Levodopa is the most effective medication for the treatment of motor symptoms of Parkinson's disease (PD). Several factors may affect the efficacy and tolerability of levodopa. These include the timing, dosage and administration of levodopa, concomitant drugs, food, PD-associated non-motor symptoms, and various neurologic and non-neurologic comorbidities. If not appropriately addressed, these issues may limit levodopa efficacy, tolerability, and compliance. Areas covered This article reviews the basics of the metabolism of orally administered levodopa, its side effects, and the factors that may affect its tolerability and efficacy. We provide several practical pearls to improve the tolerability and efficacy of levodopa. Expert opinion Protein-rich food delays and reduces levodopa absorption. Hence, levodopa should preferably be administered in a relatively empty stomach. Carbidopa dosing is crucial as it not only enhances the entry of levodopa into the central nervous system but also reduces levodopa's peripheral adverse effects. Patients experiencing the early side effects such as nausea/vomiting should be prescribed with anti-nausea medications that do not block dopamine receptors. Non-oral routes of administration can be used to obviate persistent gastrointestinal side effects. Implementation of these and other tips may help improve the tolerability and efficacy of levodopa.
引用
收藏
页码:489 / 498
页数:10
相关论文
共 90 条
[1]   Levodopa: the story so far [J].
Abbott, Alison .
NATURE, 2010, 466 (7310) :S6-S7
[2]   L-Dopa-induced sedation:: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers [J].
Andreu, N ;
Chalé, JJ ;
Senard, JM ;
Thalamas, C ;
Montastruc, JL ;
Rascol, O .
CLINICAL NEUROPHARMACOLOGY, 1999, 22 (01) :15-23
[3]  
Mena MA, 2009, CURR TOP MED CHEM, V9, P880
[4]  
Arnold G, 1997, Parkinsonism Relat Disord, V3, P191, DOI 10.1016/S1353-8020(97)00032-1
[5]   CLINICAL AND PHARMACOKINETIC EFFECTS OF A DIET RICH IN INSOLUBLE FIBER ON PARKINSON DISEASE [J].
ASTARLOA, R ;
MENA, MA ;
SANCHEZ, V ;
DELAVEGA, L ;
DEYEBENES, JG .
CLINICAL NEUROPHARMACOLOGY, 1992, 15 (05) :375-380
[6]   The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study [J].
Baba, Yasuhiko ;
Futamura, Akinori ;
Kinno, Ryuta ;
Nomoto, Shohei ;
Takahashi, Seiya ;
Yasumoto, Taro ;
Osakabe, Yuyuko ;
Shoji, Daiki ;
Nabeshima, Yoko .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2022, 437
[7]   INFLUENCE OF MEAL INGESTION TIME ON PHARMACOKINETICS OF ORALLY-ADMINISTERED LEVODOPA IN PARKINSONIAN-PATIENTS [J].
BARUZZI, A ;
CONTIN, M ;
RIVA, R ;
PROCACCIANTI, G ;
ALBANI, F ;
TONELLO, C ;
ZONI, E ;
MARTINELLI, P .
CLINICAL NEUROPHARMACOLOGY, 1987, 10 (06) :527-537
[8]   Behavioral Effects of Levodopa [J].
Beaulieu-Boire, Isabelle ;
Lang, Anthony E. .
MOVEMENT DISORDERS, 2015, 30 (01) :90-102
[9]   Mechanisms of peripheral levodopa resistance in Parkinson's disease [J].
Beckers, Milan ;
Bloem, Bastiaan R. ;
Verbeek, Marcel M. .
NPJ PARKINSONS DISEASE, 2022, 8 (01)
[10]  
Beckwith M C., 2004, HOSP PHARM, V39, P225, DOI 10.1177/001857870403900308